Time trade-off procedure for measuring health utilities loss with human papillomavirus-induced diseases: A multicenter, retrospective, observational pilot study in Italy

Clinical Therapeutics

Volumn 33, Issue 8, 2011, Pages

  Mennini, Francesco Saverio ^a   Panatto, Donatella ^b   Marcellusi, Andrea ^a   Cristoforoni, Paolo ^c   De Vincenzo, Rosa ^d   Di Capua, Elisa ^c   Ferrandina, Gabriella ^e   Petrillo, Marco ^d   Sasso, Tiziana ^b   Ricci, Cristina ^d   Trivellizzi, Nausica ^d   Capone, Alessandro ^f   Scambia, Giovanni ^d   Gasparini, Roberto ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f UNIVERSITY OF READING   (United Kingdom)

Author keywords

Anogenital warts; Cervical cancer; CIN2 3; HPV; Quality of life; TTO; Utilities

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; FEASIBILITY STUDY; FEMALE; HEALTH STATUS; HUMAN; ITALY; MULTICENTER STUDY; PILOT STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RETROSPECTIVE STUDY; SAMPLE SIZE; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

EID: 80051609896     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.06.012     Document Type: Article

References (55)

1. Bosch F.X., Lorincz A., Munoz N., et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55:244-265.
2. Snijders P.J., Steenberger R.D., Heideman D.A., Meijer C.J. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006, 208:152-164.
3. Weinstock H., Berman S., Caces W. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health 2004, 36:6-10.
4. Munoz N., Bosch F.X., de Sanjose S., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
5. de Villiers E.M., Fauquet C., Broker T.R., et al. Classification of papillomaviruses. Virology 2004, 324:17-27.
6. Lowy D.R., Frazer I.H. Chapter 16: Prophylactic human papillomavirus vaccines. J Natl Cancer Inst Monogr 2003, 31:111-116.
7. Ferlay J., Bray F., Pisani P., Parkin D.M. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. Release September 16, 2005 Descriptive Epidemiology Group of International Agency for Research on Cancer, Accessed September 2009. http://www-dep.iarc.fr.
8. Cutts F.T., Franceschi S., Goldie S., et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 2007, 85:719-726.
9. Sanders G.D., Taira A.V. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003, 9:37-48.
10. Kulasingam S.L., Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programmes. JAMA 2003, 290:781-789.
11. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programmes. Emerg Infect Dis 2004, 10:1915-1923.
12. Goldie S.J., Kholi M., Grima D., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004, 96:604-615.
13. Barnabas R.V., Laukkanen P., Koskela P., et al. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006, 3:624-632.
14. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007, 13:28-41.
15. Favato G., Pieri V., Mills R. Cost-effective analysis of anti-HPV vaccination programme in Italy: a multi-cohort Markov model Accessed October 2009. http://www.ssrn.com/abstract=961847.
16. Chesson H.W., Ekwueme D.U., Saraiya M., Markowitz L.E. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis 2008, 14:244-251.
17. Jit M., Choi Y.H., Edmunds W.J. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769.
18. Kim J.J., Goldie S.J. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008, 359:821-832.
19. Kim J.J., Ortendahl J., Goldie S.J. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009, 151:538-545.
20. Mennini F.S., Giorgi Rossi P., Palazzo F., Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009, 112:370-376.
21. Mennini F.S., Costa S., Favato G., Picardo M. Anti-HPV vaccination: A review of recent economic data for Italy. Vaccine 2009, 27:A54-A61.
22. Guide to the methods of technology appraisal (reference N0515) National Institute for Health and Clinical Excellence, Accessed September 2009. http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf.
23. Pliskin J.S., Shepard D.S., Weinstein M.C. Utility functions for life years and health status. Operations Res 1980, 28:206-224.
24. Loomes G. Disparities between health state measures: is there a rational explanation?. The Economics of Rationality 1993, 149-178. Routledge, London, UK. G. Bed (Ed.).
25. Mehrez A., Gafni A. Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs). Pharmacoeconomics 1992, 1:338-345.
26. Sassi F., Archard L., Le Grand J. Equity and the economic evaluation of healthcare. Health Technology Assessment 2001, 5:1-138.
27. Arnesen T., Trommald M. Roughly right or precisely wrong?. Systematic review of quality-of-life weights elicited with the time trade-off method. J Health Serv Res Policy 2004, 9:43-50.
28. Miyamoto J.M., Eraker S.A. Parameter estimates for a QALY utility model. Med Decis Making 1985, 5:191-213.
29. Sassi F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan 2006, 21:402-408.
30. Guidelines for classification and implementation of observational studies on drugs Italian Medicines Agency, Accessed September 2009. http://www.agenziafarmaco.it/sites/default/files/det_20marzo2008.pdf.
31. Ferrandina G., Marcellusi A., Mennini F.S., et al. Hospital costs incurred by the Italian National Health Service for invasive cervical cancer. Gynecol Oncol 2010, 119:243-249.
32. Costa S., Venturoli S., Mennini F.S., et al. Population-based frequency assessment of HPV-induced lesions in patients with borderline Pap tests in the Emilia-Romagna Region: the PATER study. Curr Med Res Opin 2011, 27:569-578.
33. Torrance G.W., Tomas W.H., Sackett D.L. A Utility maximization model for evaluation of heath care programs. Health Serv Res 1972, 7:118-133.
34. Torrance G.W. Social preferences for health states: an empirical evaluation of three measurement techniques. Socioeconomic Plan Sci 1976, 10:129-136.
35. Gafni A., Torrance G.W. Risk attitude and time preference in health. Manage Sci 1984, 30:440-451.
36. Furlong W., Feeny D., Torrance G.W., et al. Guide to design and development of health-state utility instrumentation Accessed September 2009. http://www.chepa.org/Files/Working%20Papers/WP%2090-9.pdf.
37. Italian Population Mortality Tables by province and region of residence The National Institute of Statistics, Accessed September 2009. http://demo.istat.it/index_e.html.
38. Rabin R., de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343.
39. Gold M.R., Siegel J.E., Russel L.B., Weinstein M.C. Cost-Effectiveness in Health and Medicine 1996, Oxford University Press, New York, NY.
40. Drummond M.B., O'Brien B., Stoddart G.L., Torrance G.W. Methods for the Economic Evaluation of Health Care Programmes 1997, Oxford University Press, Oxford, UK.
41. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3), December 2008 Australian Government, Department of Health and Ageing, Accessed July 2011. http://www.pbs.gov.au/pbs/pdf-viewer?pdf=%2Findustry%2Flisting%2Felements%2Fpbac-guidelines%2FPBAC4.3.2.pdf.
42. Churchill D., Morgan J., Torrance G. Quality of life in end-stage renal disease. Periton Dial Bull 1984, 4:20-23.
43. Churchill D.N., Torrance G.W., Taylor D.W., et al. Measurement of quality of life in end-stage renal disease: the time trade-off approach. Clin Invest Med 1987, 10:14-20.
44. Hornberger J.C., Redelmeier D.A., Petersen J. Variability among methods to assess patients' well-being and consequent effect on a cost-effectiveness analysis. J Clin Epidemiol 1992, 45:505-512.
45. Molzahn A.E., Northcott H.C., Hayduk L. Quality of life of patients with end stage renal disease: a structural equation model. Qual Life Res 1996, 5:426-432.
46. Lenert LA, Hornberger JC. Computer-assisted quality of life assessment for clinical trials. Proceedings of the American Medical Informatics Association, Annual Fall Symposium. 1996:992-996.
47. Sesso R., Yoshihiro M.M. Time of diagnosis of chronic renal failure and assessment of quality of life in haemodialysis patients. Nephrol Dial Transplant 1997, 12:2111-2116.
48. Hamel M.B., Phillips R.S., Davis R.B., et al. Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. Ann Intern Med 1997, 127:195-202.
49. Llewellyn-Thomas H., Sutherland H.J., Tibshirani R., et al. Describing health states. Methodologic issues in obtaining values for health states. Med Care 1984, 22:543-552.
50. McNeil B.J., Pauker S.G., Tversky A. On the framing of medical decisions. Decision Making: Descriptive, Normative, and Prescriptive Interactions 1988, 562-568. Cambridge University Press, Cambridge, UK. D.E. Bell, H. Raiffa, A. Tversky (Eds.).
51. Woloshin S., Schwartz L.M., Moncur M., et al. Assessing values for health: numeracy matters. Med Decis Making 2001, 21:382-390.
52. Goldstein M.K., Miller D.E., Davies S., Garber A.M. Quality of life assessment software for computer-inexperienced older adults: multimedia utility elicitation for activities of daily living. Proc AMIA Symp 2002, 295-299.
53. Lenert L.A., Hornberger J.C. Computer-assisted quality of life assessment for clinical trials. Proc AMIA Annu Fall Symp 1996, 992-996. Accessed October 2009. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2233008/pdf/procamiaafs00002-1025.pdf.
54. Kerlinger F.N. Foundations of Behavioral Research 1986, CBS College Publishing, New York, NY. 3rd ed.
55. Goldstein M., Tsevat J. Applying utility assessment at the "bedside.". Decision Making in Health Care: Theory, Psychology, and Applications 2000, 313. Cambridge University Press, Cambridge, UK. G.B. Chapman, F.A. Sonnenberg (Eds.).